199 related articles for article (PubMed ID: 35045666)
1. [Expert consensus on laboratory standardized technical specifications for monitoring minimal residual disease using next-generation sequencing in multiple myeloma(2021)].
;
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):974-977. PubMed ID: 35045666
[No Abstract] [Full Text] [Related]
2. [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].
Wang QQ; Yao L; Zhu MQ; Yan LZ; Jin S; Shang JJ; Shi XL; Zhai YY; Yan S; Yao WQ; You HY; Wu DP; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):328-332. PubMed ID: 37357003
[No Abstract] [Full Text] [Related]
3. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
Gozzetti A; Bocchia M
Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].
Nihon Rinsho; 2016 Jul; 74 Suppl 5():565-9. PubMed ID: 30714704
[No Abstract] [Full Text] [Related]
6. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.
Bal S; Weaver A; Cornell RF; Costa LJ
Br J Haematol; 2019 Sep; 186(6):807-819. PubMed ID: 31364160
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.
Soh KT; Wallace PK
Curr Protoc Cytom; 2019 Sep; 90(1):. PubMed ID: 31608132
[TBL] [Abstract][Full Text] [Related]
9. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
Nishihori T; Song J; Shain KH
Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557
[TBL] [Abstract][Full Text] [Related]
10. Standardisation of minimal residual disease in multiple myeloma.
Innao V; Allegra A; Russo S; Gerace D; Vaddinelli D; Alonci A; Allegra AG; Musolino C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28671297
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
13. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
14. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
15. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
16. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
[TBL] [Abstract][Full Text] [Related]
17. A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.
Takamatsu H; Wee RK; Zaimoku Y; Murata R; Zheng J; Moorhead M; Carlton VEH; Kong KA; Takezako N; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Br J Haematol; 2018 Nov; 183(4):664-668. PubMed ID: 29270982
[No Abstract] [Full Text] [Related]
18. Molecular Diagnostics of Plasma Cell Neoplasms.
Fitzpatrick MJ; Murali MR; Nardi V
Surg Pathol Clin; 2023 Jun; 16(2):401-410. PubMed ID: 37149365
[TBL] [Abstract][Full Text] [Related]
19. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
Rawstron AC; Paiva B; Stetler-Stevenson M
Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
[TBL] [Abstract][Full Text] [Related]
20. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Holstein SA; Bahlis N; Bergsagel PL; Bhutani M; Bolli N; Brownstein C; Demolis P; Foureau D; Gay F; Ghobrial IM; Gormley N; Hillengass J; Kaiser M; Maus MV; Melenhorst JJ; Merz M; Dwyer MO; Paiva B; Pasquini MC; Shah N; Wong SW; Usmani SZ; McCarthy PL
Transplant Cell Ther; 2021 Oct; 27(10):807-816. PubMed ID: 34107340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
